CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-12-23): Palliative photodynamic therapy improves survival in bile duct cancer

Clinical

Palliative photodynamic therapy improves survival in bile duct cancer

Last Updated: 2005-12-23 7:30:11 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In patients with nonresectable bile duct cancer, photodynamic therapy (PDT) designed to reduce bile duct stenosis improves quality of life and substantially prolongs survival time, physicians in Germany report.

Preliminary uncontrolled studies of photodynamic therapy have demonstrated "astonishingly good results," Dr. Thomas Zoepf and his associates note in their paper in the American Journal of Gastroenterology for November.

Dr. Zoepf, from University Hospital Essen, and his team conducted a prospective trial in which patients with advanced nonresectable bile duct cancer were randomly assigned to an endoprosthesis alone or an endoprosthesis plus PDT (16 patients in each group).

PDT involved IV administration of the hematoporphyrin derivative Photosan 3 (SeeLab, Wesselburenerkoog, Germany), followed 2 days later with laser irradiation administered either through transpapillary access or percutaneously.

"Four weeks after initial PDT, most PDT-patients showed an almost complete elimination of bile duct stenosis in the treated area as demonstrated by cholangiography," the authors report.

Median survival was 21 months in the PDT group versus 7 months in the control group (p = 0.01). The investigators also note that among the eight patients in the PDT group who initially required percutaneous transhepatic drainage, four could be converted to transpapillary access, representing a "significant improvement in the quality of life."

There were four serious infections in the PDT group as opposed to one in the control group. However, these occurred in the early phase of the study when only 3 days of antibiotics was given; there were no more serious infections once coverage was increased to 14 days.

Dr. Zoepf's group recommends larger clinical trials to confirm their results. Moreover, they add, "as hematoporphyrins also have radiosensitizing properties, a combination of PDT and radiotherapy may further improve tumor response and survival time in future."

Am J Gastroenterol 2005;100:2426-2430.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.